Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Harris, M.I. (2000) Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care, 23, 754-8.
Massi-Benedetti, M. (ed) (2002) The cost of diabetes type II in Europe. The CODE-2 study. Diabetologia, 45 (Suppl 1), S1-28.
International Diabetes Forum (2006) Prevalence of Diabetes, http://www.idf.org/home/index.cfm (accessed 14 March 2006), International Diabetes Forum.
Scheen, A.J. and Lefèbvre, P.J. (2000) Insulin resistance versus insulin deficiency: which one comes first? The old question revisited, in Diabetes in the New Millennium (eds U. Di Mario, F. Leonetti, G. Pugliese, et al.), John Wiley & Sons, Ltd, New York, pp. 101-13.
Kahn, S.E. (2003) The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia, 46, 3-19.
Stumvoll, M., Goldstein, B.J. and van Haeften, T.W. (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet, 365, 1333-46.
Grundy, S.M., Cleeman, J.I., Daniels, S.R. et al. (2005) Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 112, 2735-52.
King, H., Aubert, R.E. and Herman, W.H. (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care, 21, 1414-31.
Scheen, A.J. (2001) Obesity and diabetes, in The Management of Obesity and Related Disorders (ed P.G. Kopelman), Martin Dunitz, London, UK, pp. 11-44.
Scheen, A.J. and Lefèbvre, P.J. (1996) Patho physiology of type 2 diabetes, in Handbook of Experimental Pharmacology, Oral Antidiabetics, (eds J. Kuhlmann and W. Puls), Springer-Verlag, Berlin, pp. 7-42.
Edelstein, S.L., Knowler, W.C. Bain, R.P. et al. (1997) Predictors of progression from impaired glucose tolerance to NIDDM. An analysis of six prospective studies. Diabetes, 46, 701-10.
Harris, R., Donahue, K., Rathore, S.S. et al. (2003) Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 138, 215-29.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) Report on the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 20, 1183-97.
WHO Study Group (1994) Prevention of diabetes mellitus: report of WHO study group. WHO Technical Report Series, 844, WHO, Geneva, pp. 1-100.
Donelly, R. and Garber, A. (eds) (2001) Progression of type 2 diabetes-inevitable or preventable? Diabetes, Obesity and Metabolism, 3 (Suppl 1), S1-43.
American Diabetes Association and National Institute of Diabetes, Digestive and Kidney Diseases (2002) The prevention or delay of type 2 diabetes. Diabetes Care, 25, 742-9.
Tuomilehto, J., Lindstrom, J., Ericksson J.G. et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New England Journal of Medicine, 344, 1343-50.
Knowler, W.C., Barrett-Connor, E., Fowler, S.E. et al. (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine, 346, 393-403.
Scheen, A.J. (2003) Current management strategies for coexisting diabetes mellitus and obesity. Drugs, 63, 1165-84.
Zimmet, P., Shaw, J. and Alberti, K.G.M.M. (2003) Preventing type 2 diabetes and the dys-metabolic syndrome in the real world: a realistic view. Diabetic Medicine: A Journal of the British Diabetic Association, 20, 693-702.
Davies, M.J., Tringham, J.R., Troughton, J. and Khunti, K.K. (2004) Prevention of type 2 diabetes mellitus: a review of the evidence and its application in a UK setting. Diabetic Medicine: A Journal of the British Diabetic Association, 21, 403-14.
Schulze, M.B. and Hu, F.B. (2005) Primary prevention of diabetes: what can be done and how much can be prevented? Annual Review of Public Health, 26, 445-67.
Simpson, R.W., Shaw, J.E. and Zimmet, P.Z. (2003) The prevention of type 2 diabetes-lifestyle change or pharmacotherapy? Diabetes Research and Clinical Practice, 103, 357-62.
Liberopoulos, E.N., Tsouli, S., Mikhailidis, D.P. and Elisaf, M.S. (2006) Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Current Drug Targets, 7, 211-28.
Chiasson, J.L. and Rabasa-Lhoret, R. (2004) Prevention of type 2 diabetes: insulin resistance and beta-cell function. Diabetes, 53 (Suppl 3), S34-8.
Freemark, M. (2003) Pharmacologic approaches to the prevention of type 2 diabetes in high risk pediatric patients. The Journal of Clinical Endocrinology and Metabolism, 88, 3-13.
Krentz, A.J. and Bailey, C.J. (2005) Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs, 65, 385-411.
Padwal, R., Majumdar, S.R., Johnson, J.A. et al. (2005) A systematic review of drug therapy to delay or prevent type 2 diabetes. Diabetes Care, 28, 736-44.
Anderson, D.C. Jr (2005) Pharmacologic prevention or delay of type 2 diabetes mellitus. The Annals of Pharmacotherapy, 39, 102-9.
Buchanan, T.A. (2003) Prevention of type 2 diabetes. What is it really? Diabetes Care, 26, 1306-8.
Scheen, A.J. (2003) Preventing, delaying or masking type 2 diabetes with metformin in the Diabetes Prevention Program? Diabetes Care, 26, 2701.
McGarry, J.D. and Dobbins, R.L. (1999) Fatty acids, lipotoxicity and insulin secretion. Diabetologia, 42, 128-38.
Scheen, A.J. (2004) Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs, 64, 2537-65.
Barrett-Connor, E., Grady, D. and Stefanick, M.L. (2005) The rise and fall of menopausal hormone therapy. Annual Review of Public Health, 26, 115-40.
Eddy, D.M., Schlessinger, L. and Kahn, R. (2005) Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Annals of Internal Medicine, 143, 251-64.
Nathan, D.M., Buse, J.B., Davidson, M.B. et al. (2006) Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 29, 1963-72; and (2006) Diabetologia, 49, 1711-21.
Cusi, K. and DeFronzo, R.A. (1998) Metformin: a review of its metabolic effects. Diabetes Forecast, 6, 89-131.
Fontbonne, A., Charles, M.A. and Juhan-Vague, I. (1994) The effect of metformin on the metabolic abnormalities associated with upper body fat distribution. BIGPRO Study Group. Diabetes Care, 19, 920-6.
Tiikkainen, M., Häkkinen, A.-M. and Korsheninnikova, E. et al. (2004) Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes, 53, 2169-76.
Freemark, M. and Bursey, D. (2001) The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyper-insulinemia and a family history of type 2 diabetes. Pediatrics, 107, 1-7.
Scheen, A.J., Letiexhe, M.R. and Lefèbvre, P.J. (1995) Short administration of metformin im proves insulin sensitivity in obese android subjects with impaired glucose tolerance. Diabetic Medicine: A Journal of the British Diabetic Association, 12, 985-9.
Diabetes Prevention Program Research Group (2003) Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care, 26, 977-80.
Scheen, A.J., Letiexhe, M.R. and Lefèbvre, P.J. (1995) Effects of metformin in obese patients with impaired glucose tolerance. Diabetes/Metabolism Reviews, 11, S69-80.
Yang, W., Lin, L. and Qi, J. (2001) The preventive effect of acarbose and metformin on the IGT population from becoming diabetes mellitus: a 3-year multicentre prospective study. Chinese Journal of Endocrinology and Metabolism, 17, 131-6.
Holman, R.R., Blackwell, L. Stratton, I.M. et al. (2003) Six-year results from the early diabetes intervention trial (abstract). Diabetic Medicine: A Journal of the British Diabetic Association, 20 (Suppl 2), S15.
Ramachandran, A., Snehalatha, C., Mary, S. et al. (2006) The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia, 49, 289-97.
Ferrannini, E., Gastaldelli, A. Miyazaki, Y. et al. (2005) β-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. The Journal of Clinical Endocrinology and Metabolism, 90, 493-500.
Rendell, M. (2004) The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs, 64, 1339-58.
Alberti, K.G.M.M. (1996) The clinical implications of impaired glucose tolerance. Diabetic Medicine: A Journal of the British Diabetic Association, 13, 927-37.
Keen, H., Jarrett, R.J., Ward, J.D. and Fuller, J.H. (1973) Boderline diabetics and their response to tolbutamide. Advances in Metabolic Disorders, 2 (Suppl 2), 521-31.
Sartor, G., Schersten, B. Carlstrom, S. et al. (1980) Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes, 29, 41-9.
Herlihy, O.M., Morris, R.J., Karunakaran, S. and Holman, R. (2000) Sulphonylurea therapy over six years does not delay progression to diabetes (abstract). Diabetologia, 43 (Suppl 1), A73.
Lindblad, U., Lindwall, K., Sjostrand, A. et al. (2001) The NEPI Antidiabetes Study (NANSY). 1. Short-term dose-effect relations of glimepiride in subjects with impaired fasting glucose. Diabetes, Obesity and Metabolism, 3, 443-51.
Dornhorst, A. (2001) Insulinotropic meglitinide analogues. Lancet, 358, 1709-16.
The NAVIGATOR Trial Steering Committee (2002) Nateglinide and valsartan in impaired glucose tolerance outcomes research, rationale and design of the NAVIGATOR trial (abstract). Diabetes, 51 (Suppl 2), A116.
Gautier, J.F., Fetita, S., Sobngwi, E. and Salaun-Martin, C. (2005) Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes and Metabolism, 31, 233-42.
Yki-Järvinen, H. (2004) Thiazolidinediones. New England Journal of Medicine, 351, 1106-18.
Leiter, L.A. (2005) beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in type 2 diabetes. Diabetic Medicine: A Journal of the British Diabetic Association, 22, 963-72.
Walter, H. and Lubben, G. (2005) Potential role of oral thiazolidinedione therapy in preservation of beta-cell function in type 2 diabetes mellitus. Drugs, 65, 1-13.
Buchanan, T.A., Xiang, A.H., Peters, R.K. et al. (2002) Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes, 51, 2796-803.
Scheen, A.J. (2001) Hepatotoxicity with thiazo-lidinediones. Is it a class effect? Drug Safety: An International Journal of Medical Toxicology and Drug Experience, 24, 873-88.
Xiang, A.H., Peters, R.K., Kjos, S.L. et al. (2006) Effect of pioglitazone on pancreatic β-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes, 55, 517-22.
Durbin, R.J. (2004) Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes, Obesity and Metabolism, 6, 280-5.
The Diabetes Prevention Program Research Group (2005) Prevention of type 2 diabetes with trogli-tazone in the Diabetes Prevention Program. Diabetes, 54, 1150-6.
The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trials Investigators (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet, 368, 1096-105.
Scheen, A.J. (2007) Antidiabetic agents inpatients with mild dysglycaemia: prevention or early treatment of type 2 diabetes? Diabetes and Metabolism, 33, 3-12.
Zinman, B., Harris, S.B., Gerstein, H.C. et al. (2006) Preventing type 2 diabetes using combination therapy: design and methods of the Canadian Normoglycaemia Outcomes Evaluation (CANOE) trial. Diabetes, Obesity and Metabolism, 8, 531-7.
Lebovitz, H.E. (1998) α-Glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Forecast, 6, 132-45.
Scheen, A.J. (2003) Is there a role to α-glucosidase inhibitors in the prevention of type 2 diabetes? Drugs, 63, 933-51.
Chiasson, J.-L., Josse, R.G., Gomis, R. et al. (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet, 359, 2072-7.
Kaiser, T. and Sawicki, P.T. (2004) For debate. Acarbose for prevention of diabetes, hypertension and cardiovascular events? A critical analysis of the STOP-NIDDM data. Diabetologia, 47, 575-80.
Chiasson, J-L., Josse, R.G., Gomis, R. et al. (2004) Acarbose for the prevention of type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM trial data. Diabetologia, 47, 969-75.
Josse, R.G., McGuire, A.J. and Saal, G.B. (2006) A review of the economic evidence for acarbose in the prevention of diabetes and cardiovascular events in individuals with impaired glucose tolerance. International Journal of Clinical Practice, 60, 847-55.
Gerstein, H.C. and Rosenstock, J. (2005) Insulin therapy in people who have dysglycemia and type 2 diabetes mellitus: can it offer both cardiovascular protection and beta-cell preservation? Endocrinology and Metabolism Clinics of North America, 34, 137-54.
Rosenfalck, A.M., Hendel, H., Rasmussen, M.H. et al. (2002) Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects. Diabetes, Obesity and Metabolism, 4, 19-28.
Norris, S.L., Zhang, X., Avenell, A. et al. (2005) Long-term non-pharmacological weight loss interventions for adults with prediabetes. Cochrane Database of Systematic Reviews (Online: Update Software), 3 (Art. No.: CD005270), DOI: 10.1002/14651858.CD005270.
Hamman, R.F., Wing, R.R., Edelstein, S.L. et al. (2006) Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care, 29, 2102-7.
Padwal, R., Li, S.K. and Lau, D.C. (2004) Long term pharmacotherapy for obesity and overweight. Cochrane Database of Systematic Reviews (Online: Update Software), 3 (Art. No.: CD004094), DOI: 10.1002/14651858.CD004094.pub2.
Li, Z., Maglione, M., Tu, W. et al. (2005) Metaanalysis: pharmacologic treatment of obesity. Annals of Internal Medicine, 142, 532-46.
Curran, M.P. and Scott, L.J. (2004) Orlistat: a review of its use in the management of patients with obesity. Drugs, 64, 2845-64.
Norris, S.L., Zhang, X., Avenell, A. et al. (2005) Pharmacotherapy for weight loss in adults with type 2 diabetes. Cochrane Database of Systematic Reviews (Online: Update Software), 1 (Art. No.: CD004096), DOI: 10.1002/14651858.CD004096.pub2.
Scheen, A.J. and Ernest, P. (2002) Antiobesity treatment in type 2 diabetes: results of clinical trials with orlistat and sibutramine. Diabetes and Metabolism, 28, 437-45.
Kelley, D.E., Kuller, L.H., McKolanis, T.M. et al. (2004) Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care, 27, 33-40.
Tiikkainen, M., Bergholm, R., Rissanen, A. et al. (2004) Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women. The American Journal of Clinical Nutrition, 79, 22-30.
Heysmfield, S.B., Segal, K.R., Hauptman, J. et al. (2000) Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Archives of Internal Medicine, 160, 1321-6.
Keating, G.M. and Jarvis, B. (2001) Orlistat in the prevention and treatment of type 2 diabetes mellitus. Drugs, 61, 2107-19.
Torgerson, J.S., Hauptman, J., Boldrin, M.N. and Sjöström, L. (2004) Xenical in the Prevention of Diabetes in Obese Subjects (XENDOS) study. A randomised study of orlistat as an adjunct to lifestyle for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27, 155-61.
McNeely, W. and Goa, K.L. (1998) Sibutramine. A review of its contribution in the management of obesity. Drugs, 56, 1093-124.
Filippatos, T.D., Kiotsis, D.N., Liberopoulos, E.N. et al. (2005) A review of the metabolic effects of sibutramine. Current Medical Research and Opinion, 21, 457-68.
Arterburn, D.E., Crane, P.K. and Veenstra, D.L. (2004) The efficacy and safety of sibutramine for weight loss: a systematic review. Archives of Internal Medicine, 164, 994-1003.
Vettor, R., Serra, R., Fabris, R. et al. (2005) Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care, 28, 942-9.
James, W.P.T., Astrup, A., Fier, N. et al. (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet, 356, 2119-25.
James, W.P.T. (2005) The SCOUT study: risk-benefit profile of sibutramine in overweight high-risk cardiovascular patients. European Heart Journal, 7 (Suppl L), L44-8.
Di Marzo, V., Bifulco, M. and De Petrocellis, L. (2004) The endocannabinoid system and its therapeutic exploitation. Nature Reviews. Drug Discovery, 3, 771-84.
Pagotto, U., Marsicano, G., Cota, D. et al. (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews, 27, 73-100.
Van Gaal, L.F., Rissanen, A.M., Scheen, A.J. et al. (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 365, 1389-97.
Després, J.P., Golay, A. and Sjöström, L. (2005) Effect of rimonabant on body weight and the metabolic syndrome in overweight patients. New England Journal of Medicine, 353, 2121-34.
Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M. et al. (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. The Journal of the American Medical Association, 295, 761-75.
Scheen, A.J., Finer, N., Hollander, P. et al. (2006) Effects of rimonabant on body weight, glucose control, and cardiometabolic risk factors in patients with type 2 diabetes. Lancet, 368, 1660-73.
Van Gaal, L.F., Pi-Sunyer, X., Després, J.P. et al. (2008) Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the RIO program. Diabetes Care, 31 (Suppl 2), S229-40.
Van Gaal, L.F., Scheen, A.J., Rissanen, A.M. et al. (2008) RIO-Europe 2-year. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two-year results from the RIO-Europe study. European Heart Journal, DOI: 10.1093/eurheart/ehn076.
Rosenstock, J. (2005) The potential of rimonabant in prediabetes: pooled 1-year results from the RIO-Lipids, RIO-Europe and RIO-North America studies (abstract). Diabetologia, 48 (Suppl 1), A16.
Taskinen, M.R. (2005) Type 2 diabetes as a lipid disorder. Current Molecular Medicine, 5, 297-308.
Boden, G. (1997) Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes, 45, 3-10.
Lewis, G.F., Carpentier, A., Adeli, K. and Giacca, A. (2002) Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrine Reviews, 23, 201-29.
Paolisso, G., Barbagallo, M., Petrella, G. et al. (2000) Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis, 150, 121-7.
Karhapää, P., Uusitupa, M., Voutilainen, E. and Laakso, M. (1992) Effect of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidaemia. Clinical Pharmacology and Therapeutics, 52, 620-6.
Vuorinen-Markkola, H., Yki-Järvinen, H. and Taskinen, M.-R. (1993) Lowering of triglycerides by gemfibrozil affects neither the glucoregula-tory nor antilipolytic effect of insulin in type 2 (non-insulin-dependent) diabetic patients. Dia-betologia, 36, 161-9.
Kahn, S.E., Beard, J.C., Schwartz, M.W. et al. (1989) Increased beta-cell secretory capacity as mechanism for islet adaptation to nicotinc acid-induced insulin resistance. Diabetes, 38, 562-8.
Bonetti, P.O., Leman, L.O., Napoli, C. and Lerman, A. (2003) Statin effects beyond lipid lowering-are they clinically relevant? European Heart Journal, 24, 225-48.
Freeman, D.J., Norrie, J., Sattar, N. et al. (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation, 103, 357-62.
Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals. Lancet, 360, 7-22.
Keech, A., Colquhoun, D., Best, J. et al. (2003) Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose. Diabetes Care, 26, 2713-21.
Sever, P.S., Dahlof, B., Poulter, N.R. et al. (2003) Prevention of coronary and stroke events with ator-vastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): amul-ticentre randomised controlled trial. Lancet, 361, 1149-58.
Yee, A., Majumdar, S.R., Simpson, S.H. et al. (2004) Statin use in type 2 diabetes mellitus is associated with a delay in starting insulin. Diabetic Medicine: A Journal of the British Diabetic Association, 21, 962-7.
Jick, S.S. and Bradbury, B.D. (2004) Statins and newly diagnosed diabetes. British Journal of Clinical Pharmacology, 58, 303-9.
Staels, B. and Fruchart, J.C. (2005) Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes, 54, 2460-70.
Tenenbaum, A., Motro, M., Fisman, E.Z. et al. (2004) Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation, 109, 2197-202.
Vega, G.L., Cater, N.B., Meguro, S. and Grundy, S.M. (2005) Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipi-demia. The American Journal of Cardiology, 95, 1309-13.
Shepherd, J., Betteridge, J. and Van Gaal, L. (2005) Nicotinic acid in the management of dys-lipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Current Medical Research and Opinion, 21, 665-82.
Abuissa, H., Jones, P.G., Marso, S.P. and O'Keefe, J.H. (2005) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes. A meta-analysis of randomized clinical trials. Journal of the American College of Cardiology, 46, 821-6.
Gillespie, E.L., White, C.M., Kardas, M. et al. (2005) The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care, 28, 2261-6.
Vijayaraghavan, K. and Deedwania, P.C. (2005) The renin angiotensin system as a therapeutic target to prevent diabetes and its complications. Cardiology Clinics, 23, 165-83.
Gress, T.W., Nieto, F.J., Shahar, E. et al. (2000) Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. New England Journal of Medicine, 342, 905-12.
Padwal, R. and Laupacis, A. (2004) Antihypertensive therapy and incidence of type 2 diabetes. A systematic review. Diabetes Care, 27, 247-55.
Pepine, C.J. and Cooper-DeHoff, R.M. (2004) Cardiovascular therapies and risk for development of diabetes. Journal of the American College of Cardiology, 44, 509-12.
Stump, C.S., Hamilton, M.T. and Sowers, J.R. (2006) Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clinic Proceedings, 81, 796-806.
Jandeleit-Dahm, K.A., Tikellis, C., Reid, C.M. et al. (2005) Why blockade of the rennin-angiotensin system reduces the incidence of new-onset diabetes. Journal of Hypertension, 23, 463-73.
Scheen, A.J. (2004) Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes and Metabolism, 30, 498-505.
Leiter, L.A. and Lewanczuk, R.Z. (2005) Of the renin-angiotensin system and reactive oxygen species. Type 2 diabetes and angiotensin II inhibition. American Journal of Hypertension, 18, 121-8.
Tikellis, C., Cooper, M.E. and Thomas, M.C. (2006) Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes. The International Journal of Biochemistry and Cell Biology, 38, 737-51.
Scheen, A.J. (2004) Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes and Metabolism, 30, 487-96.
Hansson, L., Lindholm, L.H., Ekblom, T. et al. (1999) Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet, 354, 1751-6.
Hansson, L., Lindholm, L.H., Niskanen, L. et al. (1999) Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet, 353, 611-16.
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treat-mment to Prevent Heart Attack Trial (ALLHAT). The Journal of the American Medical Association, 288, 2981-97.
Reid, C.M., Johnston, C.I., Ryan, P. et al. (2003) Diabetes and cardiovascular outcomes in elderly subjects treated with ACE-inhibitors or diuretics: findings from the 2nd Australian National Blood Pressure Study (abstract). American Journal of Hypertension, 16, 11A.
Dahlof, B., Sever, P.S., Poulter, N.R. et al. (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, 366, 895-906.
Braunwald, E., Domanski, M.J., Fowler, S.E. et al. (2004) Angiotensin-converting-enzyme inhibition in stable coronary artery disease. New England Journal of Medicine, 351, 2058-68.
Pepine, C.J., Handberg, E.M., Cooper-DeHoff, R.M. et al. (2003) A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. The Journal of the American Medical Association, 290, 2805-16.
The European Trial on Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery Disease Investigators (EU-ROPA) (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 362, 782-8.
Yusuf, S., Sleight, P., Pogue, J. et al. (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. New England Journal of Medicine, 342, 145-53.
Yusuf, S., Gerstein, H., Hoogwerf, B. et al. (2001) Ramipril and the development of diabetes. The Journal of the American Medical Association, 286, 1882-5.
HOPE/HOPE-TOO Study Investigators (2005) Long-term effects of ramipril on cardiovascular events and on diabetes. Results of the HOPE study extension. Circulation, 112, 1339-46.
Vermes, E., Ducharme, A., Bourassa, M.G. et al. (2003) Enalapril reduces the incidence of diabetes in patients with chronic heart failure. Insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation, 107, 1291-6.
The DREAM Trial Investigators (2006) Effect of ramipril on the incidence of diabetes. New England Journal of Medicine, 355, 1551-62.
Ingelfinger, J.R. and Solomon C.G. (2006) Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance-is there still hope? New England Journal of Medicine, 355 (15), 1551-62.
Dahlöf, B., Devereux, R.B., Kjeldsen S.E. et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 359, 995-1003.
Lindholm, L.H., Ibsen, H., Borch-Johnsen, K. et al. (2002) Risk of new onset-diabetes in the Losartan Intervention for Endpoint reduction in hypertension study. Journal of Hypertension, 20, 1879-86.
Lindholm, L.H., Persson, M., Alaupovic, P. et al. (2003) Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). Journal of Hypertension, 21, 1563-74.
Julius, S., Kjeldsen, S.E. Weber, M. et al. (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 363, 2022-31.
Lithell, H., Hansson, L., Skoog, I. et al. (2003) The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. Journal of Hypertension, 21, 875-86.
Pfeffer, M.A., Swedberg, K., Granger, C.B. et al. (2003) Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 362, 759-66.
Yusuf, S., Ostergren, J.B. Gerstein, H.C. et al. (2005) Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation, 112, 48-53.
The ONTARGET Investigators (2008) Telmisar-tan, ramipril, or both in patients at high risk for vascular events. New Engl J Med, 358, 1547-59.
Schupp, M., Clemenz, M., Gineste, R. et al. (2005) Molecular characterization of new selective peroxisome proliferators-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes, 54, 3442-52.
Pershadsingh, H.A. (2006) Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferators-activated receptor-γ. The International Journal of Biochemistry and Cell Biology, 38, 766-81.
Kurtz, T.W. and Pravenec, M. (2004) Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. Journal of Hypertension, 22, 2253-61.
Louet, J.F., LeMay, C. and Mauvais-Jarvis, F. (2004) Antidiabetic actions of estrogen: insight from human and genetic mouse models. Current Atherosclerosis Reports, 6, 180-5.
Barros, R.P., Machado, U.F. and Gustafsson, J.A. Estrogen receptors: new players in diabetes mellitus. (2006) Trends in Molecular Medicine, 12, 425-31.
Manson, J.E., Rimm, E.B., Colditz, G.A. et al. (1992) A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Annals of Epidemiology, 2, 665-73.
Zhang, Y., Howard, B.V., Cowan, L.D. et al. (2002) The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in America Indian postmenopausal women: the Strong Heart Study. Diabetes Care, 25, 500-4.
Rossi, R., Origliani, G. and Modena, M.G. (2004) Transdermal 17-β-estradiol and risk of developing type 2 diabetes in a population of healthy, non-obese postmenopausal women. Diabetes Care, 27, 645-9.
Kanaya, A.M., Herrington, D., Vittinghoff, E. et al. (2003) Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study. Annals of Internal Medicine, 138, 1-9.
Margolis, K.L., Bonds, D.E., Rodabough, R.J. et al. (2004) Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia, 47, 1175-87.
Bonds, D.E., Lasser, N., Qi, L. et al. (2006) The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial. Diabetologia, 49, 459-68.
Kim, D.-J. and Barrett-Conor, E. (2006) Association of serum proinsulin with hormone re placement therapy in nondiabetic older women. The Rancho Bernardo Study. Diabetes Care, 29, 618-24.
Godsland, I.F. (2005) Oestrogens and insulin secretion. Diabetologia, 48, 2213-20.
Pickup, J.C. and Crook, M.A. (1998) Is type 2 diabetes mellitus a disease of the innate immune system? Diabetologia, 41, 1241-8.
Helmersson, J., Vessby, B., Larsson, A. and Basu, S. (2004) Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation, 109, 1729-34.
Shoelson, S.E., Lee, J. and Goldfine, A.B. (2006) Inflammation and insulin resistance. The Journal of Clinical Investigation, 116, 1793-801.
Schmidt, M.I., Duncan, B.B., Sharrett, A.R. et al. (1999) Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study): a cohort study. Lancet, 353, 1649-52.
Pradhan, A.D., Manson, J., Rifai, N. et al. (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. The Journal of the American Medical Association, 286, 327-34.
Barzilay, J.I., Araham, L., Heckbert, S.R. et al. (2001) The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes, 50, 2384-9.
Freeman, D.J., Norrie, J., Caslake, M.J. et al. (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes, 51, 1596-600.
Festa, A., D'Agostino, R. Jr, Tracy R.P. et al. (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study. Diabetes, 51, 1131-7.
Duncan, B.B., Schmidt, M.I., Pankow, J.S. et al. (2003) Low-grade systemic inflammation and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes, 52, 1799-805.
Spranger, J., Kroke, A., Mohlig, M. et al. (2003) Adiponectin and protection against type 2 diabetes. Lancet, 361, 226-8.
Duncan, B.B., Schmidt, M.I., Pankow, J.S. et al. (2004) Adiponectin and the development of type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes, 53, 2473-8.
Haffner, S. (2001) Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors. Circulation, 103, 346-7.
Deans, K.A. and Sattar, N. (2006) ''Anti inflammatory'' drugs and their effects on type 2 diabetes. Diabetes Technology and Therapeutics, 8, 18-27.
Hundal, R.S., Petersen, K.F., Mayerson, A.B. et al. (2002) Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. The Journal of Clinical Investigation, 109, 1321-6.
Möhlig, M., Freudenberg, M., Bobbert, T. et al. (2006) Acetylsalicylic acid improves lipid-induced insulin resistance in healthy men. The Journal of Clinical Endocrinology and Metabolism, 91, 964-7.
Tardiff, J.C., McMurray, J.J.V., Klug, E. et al. (2008) Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet, 371, 1761-8.
